Management volunteers specific, checkable numbers about the near future — quantified forward commitments it could visibl
The model's full reasoning — Q3 2018 call → NOWe need answer only YES or NO. Need analyze transcript for specific checkable numbers/dates volunteered by management about near-term business step-up. Let's parse. Company Agios. Q3 2018. Key updates: TIBSOVO launch, sNDA submission by end Jan 2019 for newly diagnosed AML, Phase 3 AGILE enrollment completion 2020 (a year earlier), MAA submission by end 2018, CLARITY enrollment first half 2019, mitapivat enrollment 2019, thalassemia Phase 2 by end of year, IND submitted for AG-636. Also financial guidance: cash runway through end 2020. TIBSOVO net sales $4.5M first partial quarter. No specific future revenue guidance. They mention "approximately 25% to 30% of newly diagnosed patients may not receive standard therapies" - not commitment. "we now expect to complete enrollment in 2020, a year earlier" - specific date but not a step-up? It is a timeline commitment. "submit sNDA by end of January 2019" - specific date, regulatory submission, not business activity level. "MAA submission by end of 2018" - specific. "CLARITY complete enrollment first-half 2019" - specific. "Mitapivat complete enrollment in both trials in 2019" - specific. "Phase 2 thalassemia initiate by end of year" - specific. These are milestones, not quantified business output. The question asks "VOLUNTEER SPECIFIC, CHECKABLE NUMBERS OR DATES ABOUT WHAT THE COMPANY'S OWN BUSINESS WILL DO IN THE NEAR TERM — quantified forward commitments concrete enough that investors will plainly be able to verify within roughly the next year whether management delivered — AND does management present these as commitments describing a business that is STEPPING UP from its current level, grounded in things management says it can already see?" Need decide if any such. They give dates for regulatory submissions and trial enrollment completions. Are these "numbers or dates" about business? Yes, dates. But are they "quantified forward commitments" about business doing something? They are clinical development milestones, not business activity like sales, production, customers. The prompt includes "a dated start-up, launch, or ramp with the expected size attached." Here dates for sNDA submission, MAA submission, trial enrollment completion. But no expected size attached. Also "step-up" from current level? They are advancing pipeline, but not necessarily business stepping up.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| DXLG | Destination XL Group, Inc. | Q2 2023 | 2023-08-24 | D |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
TWO · Q2 2022 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term that show a step-up, grounded in things they can already see....YES The transcript shows management volunteering a concrete, checkable commitment on the RoundPoint acquisition: they expect incremental annual pre-tax earnings of approximately $20 million once the portfolio is fully transferred (with Mary Riskey later confirming $0.45 per share after-tax accretion). They also state they will begin transitioning loans to Round Point as a subservicer later this year and expect the acquisition to close in 2023. These are presented as owned expectations tied to the in-house servicing model they are already executing, describing a clear step-up in earnings and operational activity above the current subservicing level.
CUBI · Q3 2018 → YESThe question is about whether management volunteers specific, checkable numbers or dates about the company's own business in the near term, presenting them as commitments for a step-up from current le...YES Management volunteers concrete, checkable commitments for the near term (next 12–18 months) that describe a clear step-up from current levels and are grounded in things already in motion or in hand. Examples include: - NIM target of 2.75% within 12–18 months, explicitly tied to 3–4 rate hikes and the $495 million securities sale plus $500 million borrowings repayment already executed. - $600 million core-franchise deposit growth + $500–600 million CB digital + $500 million BankMobile white-label deposits next year, building on the $1.
ADPT · Q4 2022 → YESThe question is: Does management volunteer specific, checkable numbers or dates about what the company's own business will do in the near term — quantified forward commitments concrete enough that inv...YES Management volunteers concrete, checkable commitments for 2023 that describe a clear step-up: full-year revenue of $205–215 million (versus $185.3 million in 2022), clonoSEQ test volumes growing more than 50% from the current base, MRD pharma milestones in the mid to high-single-digit millions, community business reaching 20% of total revenue (from 15% currently), and 2023 OpEx (including cost of revenue) slightly below the 2022 level of $385.5 million, with average quarterly cash burn of $40 million.